Details

Autor(en) / Beteiligte

• Operario, Darwin J
• Koeppel, Alexander F
• Turner, Stephen D
• Bao, Yongde
• Pholwat, Suporn
• Banu, Sayera
• Foongladda, Suporn
• Mpagama, Stellah
• Gratz, Jean
• Ogarkov, Oleg
• Zhadova, Svetlana
• Heysell, Scott K
• Houpt, Eric R
• Mokrousov, Igor

Titel

Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis

Ist Teil von

• PloS one, 2017-05, Vol.12 (5), p.e0176522-e0176522

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2017

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek (Open access)

Beschreibungen/Notizen

• Amplicon-based Next Generation Sequencing (NGS) is an emerging method for Mycobacterium tuberculosis drug susceptibility testing (DST) but has not been well described. We examined 158 clinical multidrug-resistant M. tuberculosis isolates via NGS of 11 resistance-associated gene regions covering 3519 nucleotides. Across these gene regions, complete resistance or heteroresistance (defined as 1%-99% mutation) was present in at least one isolate in 6.3% of loci. The number of isolates with heteroresistance was highest for gyrA codon 94, rpoB codons 526 and 531, and embB codons 306, 372 and 406 (range 11-26% of isolates exhibited heteroresistance). 57% of MDR strains had heteroresistance of one or more recognized resistance-associated mutation. Heteroresistant loci generally exhibited high or low degrees of mutation (>90% or <10%). The deep sensitivity of NGS for detecting low level pncA heteroresistance appeared to improve genotypic-phenotypic PZA susceptibility correlations over that of Sanger. NGS demonstrates that heteroresistance in TB in the regions of key genes is common and will need to be bioinformatically managed. The clinical significance of such heteroresistance is unclear, and further study of pncA should be pursued.